Our law firm is currently handling lawsuits on behalf of individuals who have been injured after being treated with Valsartan. Lawsuits against the manufacturers of Valsartan claim that patients taking contaminated batches of Valsartan to treat high blood pressure may develop cancer.
Valsartan is prescribed to patients who have heart failure, high blood pressure, and type II diabetes. Valsartan is classified as an angiotensin II receptor blocker (ARB), which works by expanding blood vessels. The U.S. Food and Drug Administration (FDA) issued a recall of Valsartan beginning in 2018 after reports that the medication was contaminated with cancer causing chemicals. The chemicals, N-nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA), have been shown to cause cancer in animals and are suspected of causing cancer in humans.
Individuals who have been harmed as a result of taking Valsartan have filed claims against several pharmaceutical companies including Alembic Pharmaceuticals Ltd., Novel Laboratories Inc., Unichem Pharmaceuticals, Teva Pharmaceuticals, and Major Pharmaceuticals. In February 2019, approximately 40 lawsuits were consolidated into a multidistrict litigation in the District of New Jersey.
Valsartan that has been contaminated with NDMA or NDEA is associated with severe kidney and liver disease and an increased risk of bladder cancer, colorectal cancer, kidney cancer, pancreatic cancer, liver cancer, esophageal cancer, prostate cancer, leukemia, non-Hodgkin’s lymphoma, and stomach cancer.
The Lake Law Firm was founded by Edward J. Lake, Esq., a personal injury lawyer for over 25 years. Our dedicated team of attorneys is committed to seeking justice on behalf of those who have suffered injury or death due to the negligence of others. Our experienced attorneys handle many different types of pharmaceutical drugs, medical devices, and other defective products. The lawyers in our firm have helped collect millions of dollars for their clients. The Lake Law Firm will advocate for you and your rights. Please contact us for a free confidential case evaluation at (888) 274-0139 or submit an inquiry on this page.
On July 13, 2018, the FDA warned the public about a voluntary recall of several medications containing Valsartan. The FDA’s investigation disclosed that the contaminant was likely introduced into the drug in the manufacturing process. Medication that was manufactured with ingredients obtained from the Chinese company, Zhejiang Huahai Pharmaceuticals, was affected. In some instances, companies had knowledge that the medication was unsafe and could have warned users about the risks of contamination.
NMDA and NDEA were classified as carcinogens in 2005. Initial reports of users experiencing adverse conditions related to recalled Valsartan were first gathered in 2015. Patients reported complications with the liver, kidney, and intestines with some developing liver and kidney cancer.